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Abstract: Cryopreservation of human gametes and embryos as well as human reproductive tissues
has been characterized as an essential process and aspect of assisted reproductive technology (ART).
Notably, sperm cryopreservation is a fundamental aspect of cryopreservation in oncological patients or patients undergoing gonadotoxic treatment. Given that there is a risk of contamination
or cross-contamination, either theoretical or real, during the procedures of cryopreservation and
cryostorage, both the European Society for Human Reproduction and Embryology (ESHRE) and
the American Society for Reproductive Medicine (ASRM) have provided updated guidelines for
preventing or reducing the contamination risk of sexually transmitted viruses. Given the ongoing
and worldwide COVID-19 pandemic, there is considerable interest in what measures should be taken
to mitigate SARS-CoV-2 contamination during cryopreservation and cryostorage of semen samples.
The SARS-CoV-2 virus is the virus that causes COVID-19, and whose transmission and infection is
mainly aerosol-mediated. Several ART professional societies, including ESHRE and ASRM have
proposed measures to mitigate the spread of the SARS-CoV-2 virus. Whether the proposed safety
directives are enough to mitigate the possible SARS-CoV-2-contamination of sperm samples during
cryopreservation or whether the policies should be re-evaluated will be discussed in this review.
Additionally, insights regarding the possible impact of COVID-19 vaccination on the safety of sperm
cryopreservation will be discussed.
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1. Introduction
Infertility affects millions of people worldwide and therefore, even during the COVID19 pandemic, it remains an important public health issue. During the first months of the
infection, many assisted reproduction technology (ART) professional societies published
detailed COVID-19 guidance for the ART health community [1,2]. Initially, recommendations called for the suspension of non-essential ART, gamete and embryo cryopreservation
services, diagnostic, and ART procedures [1,2]. These initial recommendations were established to reduce the risk of COVID-19 infections in patients and healthcare workers, and
to reduce the load on healthcare systems that were already overburdened [3]. As the pandemic evolved and effective mitigation measures were implemented, European Society for
Human Reproduction (ESHRE) and American Society for Reproductive Medicine (ASRM)
provided updated recommendations regarding the re-initiation of critical, time-sensitive
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services whilst retaining the mitigating measures proposed initially [4,5]. In vitro fertilization (IVF) clinics have had to adapt to implement additional standard operating procedures
as a precautionary measure against the highly contagious COVID-19 respiratory virus,
thereby ensuring that good laboratory practices safeguard patients, personnel, gametes,
and embryos [6–8].
Standard practice during ART is to assume any biological sample may be potentially
infectious, and as such universal precautions are utilized. However, the precautions
adopted are based on blood-borne viral infections, not respiratory-borne infections [7].
As more data on COVID-19 became available, concern was raised with the discovery of
SARS-CoV-2 receptors in human gametes and embryos [9–14]. Data are mixed and some
studies have failed to detect the virus in semen, either in acute or recovered symptomatic
male patients [15–20] while others have demonstrated the presence of SARS-CoV-2 in the
semen of affected males [21]. Conversely, Li and colleagues reported the presence of the
virus in 15.8% of semen samples tested, in patients at the acute stage of infection and
several patients who were recovering [21]. Furthermore, another study failed to detect the
virus in semen samples in patients affected with SARS-CoV-2; however, they did report
impaired semen parameters in COVID-19 male patients [16]. Both studies concluded that
the virus might be present at undetectable levels, particularly in recovered patients [16,21].
SARS-CoV-2 has also been linked to infections of the testes and epididymis [13], which may
lead to post-infectious perturbations in spermatogenesis. Furthermore, some COVID-19
patients are subjected to a hyper-inflammatory syndrome characterized by sustained fever
and potential changes in the cytokine profile which may result in potential long-term effects
on spermatogenesis [13].
A longer lasting impact of SARS-CoV-2 could be from the storage of potentially infectious material during the course of IVF. Viruses may retain their infectivity during
cryopreservation and in storage at ultra-cool temperature [22]. Thus, sperm samples contaminated with SARS-CoV-2 could potentially cross contaminate other specimens during
long term storage, making sperm cryopreservation a potentially risky ART procedure.
Although there is no evidence that an aerosol-mediated virus retains infectivity at ultra-low
temperatures, there is a “theoretical risk” of contamination [23]. Moreover, many factors
such as the dilution of semen and the processing and removal of seminal fluid during
the sperm cryopreservation process have demonstrated an impact on the presence of the
virus in contaminated samples [24,25]. A recent study reported the absence of the virus in
cryopreserved semen samples analyzed in 50 semen samples in January 2020 and 50 semen
samples in April–May 2020 from the Hunan Province Human Sperm Bank (China) [26].
The present review aims to provide insights regarding the impact of SARS-CoV-2 on
semen cryopreservation during the COVID-19 pandemic in conjunction with European
and other directives upon the appearance of the virus as well as the virus variants as
they emerge. Moreover, it will be comment on the “theoretical” and the “real” risk of
contamination during the cryopreservation procedures which are considered as threats, as
well as the appearance of the new SARS-CoV-2 variants which is also considered to be a
threat during sperm cryopreservation.
2. Guidelines for Sperm Cryopreservation of Virus-Positive Samples, Including
SARS-CoV-2
Sperm cryopreservation is standard practice within the ART community, allowing
the utilizing of cryopreserved sperm during ART treatment and also preserving male
fertility through long term sperm storage [27]. One of the concerns of long-term storage
within liquid nitrogen is the detection of at least 28 viruses [28], including the SARS-CoV-2
virus [16,21], in semen samples. Although no cross-contamination of virus has occurred
during ART (to these authors knowledge), ASRM, ESHRE, and CAP (College of American
Pathologists) have provided specific guidelines to minimize cross-contamination of viruses,
specifically sexual transmitted viruses [29–31]. Briefly, since semen samples may contain a
variety of viruses at any detection level, several risk-reduction strategies are employed to
minimize any potential risk of viral transmission during fertility treatments. One important
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measure to minimize any potential cross-contamination risk during sperm cryopreservation
is the application of good laboratory practice. Standard laboratory practices published by
ESHRE and ASRM involve repeated sperm washing steps, which lead to the significant
dilution of any virus present in the sample. In addition to the washing steps, common
semen preparation procedures (e.g., sperm swim up or density gradient centrifugation)
also offer additional advantages. Firstly, these remove the seminal fluid which contains
a significant amount of the viral load. Secondly, it separates the motile viable from the
immotile non-viable spermatozoa leading to a smaller sperm volume that needs to be
cryopreserved. Lastly, gradients and swim ups separate the sperm from other infectious
cells within the ejaculate, thereby limiting the number of infectious agents within the
sperm sample. An additional strategy that can be utilized is the use of closed vitrification
devices or specific sealing techniques, which prevents the direct contact of the infected
sample to liquid nitrogen. The use of closed systems in combination of sperm-washing
methods has been demonstrated to decrease the viral load in cryopreserved samples [32].
Alternatively, the use of liquid nitrogen vapor as opposed to liquid nitrogen for long
term storage of samples would significantly reduce the virus’s ability to migrate to other
samples [33,34]. Although there is a lack of evidence of cross-contamination either using
open or closed vitrification systems, good laboratory practices recommend that gametes
and embryos from infected patients be stored in separate containers; thus, minimizing risk
of cross-contamination (CAP checklist 2021). Additionally, a quarantine cryostorage tank
is recommended for samples of unknown status until the specimen can be assessed for
infectious potential.
Recently, the Canadian Fertility and Andrology Society published updated clinical
practice guidelines [35] on the separation of specimens of unknown status. Their position
was that the separation of specimens of unknown status is only administrative and not
scientifically evidenced-based and therefore does not require separate cryostorage equipment. Therefore, samples of known positive virus status can be stored along with other
samples [35]. Similar clinical practice guidelines for SARS-CoV-2 have been published by
the respective Italian Society [36].
The European Centre for Disease Prevention and Control (ECDC) proposed precautionary measures in order to reduce the risk of contamination of human reproductive cells
by viruses including SARS-CoV-2 [37]. Precautionary measures include the concept that
all body fluids, including semen and follicular fluid, be treated as potentially contaminated [29] helps mitigate the risk of cross-contamination. This is of importance as viruses
stored at ultra-low temperatures appear to retain their pathogenic properties [22] and
therefore it is theoretically possible that cryostorage of an infected sample poses a potential
threat even years later. Nevertheless, considering the series of events during cryopreservation the risk of cross-contamination appears to be negligible. The only examples that
have been reported for cross-contamination were experimental studies using very high
titers of infectious agents [38], which is in contrast to the cryopreservation setting of the
IVF laboratory.
3. Theoretical vs. Real Risk
There are two types of risk, theoretical and real. Theoretical risk, as the name suggests,
represents a perceived risk that could potentially occur, but has not yet. Conversely, real
risk represents an actual “non-theoretical” that must be planned for? The possibility of
SARS-CoV-2 cross-contamination during sperm cryopreservation is a “theoretical risk”.
However, if the possibility of cross-contamination is perceived as a real risk, asymptomatic
patients cryopreserving sperm at this time pose a potentially threat and challenge for ART
programs. If we accept SARS-CoV-2 is likely to be similar in terms of resistance in liquid
nitrogen as other viruses, in combination with the fact that SARS-CoV-2 may be detected
in low titers in seminal fluid, SARS-CoV-2 could be classified as a potentially sexually
transmitted disease, thus warranting the same protocols as cryopreserving samples from
patients infected with a sexual transmitted disease. Given the current scientific evidence,
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the risk remains theoretical, and in our opinion, it is unlikely to pose any significant clinical
cross-contamination risk. Additionally, there is accumulating evidence that SARS-CoV-2
is not detectable in semen of either recovered or infected patients and the fact that SARSCoV-2 is aerosol-mediated suggest that cross-contamination of this virus is in our opinion
a “theoretical risk”.
4. SARS-CoV-2 Variants and Vaccines
Theoretical risk constitutes a potential real threat with the appearance of variant
strains of SARS-CoV-2. Viruses continuously change through mutation and SARS-CoV-2
is no exception. Numerous variants of the COVID-19 virus have been reported including
variants that the Centers of Disease Control (CDC) have classified as Variants of Concern
(VOC) as these variants appear to more transmissible or deadlier than the wild-type SARSCoV-2 [39–41]. Thus, the contamination risk may need to be further evaluated with data
regarding the current and future variants. Given that several VOCs have been shown to be
more transmissible, it can be speculated that the presence of the virus in seminal fluid might
be more detectable in comparison to the wild-type strain. With the increase in the presence
and veracity of VOCs, it may be necessary to alter or address guidelines/recommendations.
Therefore, the following question remains: will good practice in IVF laboratories provide
enough protection to specimens from VOCs? One could argue that the supposed theoretical
risk in this case is potentially increased given the limited knowledge regarding the detection
levels of the variants in respective reproductive fluids. Some preliminary answers may be
derived from vaccine efficacy data. Although a variety of vaccines have been developed
aiming to mitigate the rate of COVID-19 infections, and so far, all provide some level of
immunity to the variants. However, clinical trials of multiple vaccines in South Africa,
where the B.1.351 VOC represents a significant proportion of circulating SARS-CoV-2,
reported a lower vaccine efficacy when compared with trials in other countries where
the B.1.351 was not dominant [42]. Therefore, new SARS-CoV-2 variants may need to
be thoroughly investigated further and could potentially pose a real threat for crosscontamination. A practical solution remains to follow good laboratory practice, e.g.,
implementing the recommended washing steps to decrease the viral load to levels that are
clinically insignificant. Another less practical and more costly option includes the use of
closed vitrification devices.
Currently, there are a handful of SARS-CoV-2 vaccines authorized for use by both
the European Medicines Agency and the Centers for Disease Control. These include
mRNA vaccines (BNT162b2/Comirnaty, Pfizer-BioNTech and mRNA-1273 Moderna) and
adenoviral vector-based vaccines such as the Johnson & Johnson’s Janssen COVID-19
vaccine. These vaccines target the highly conserved spike protein that is involved in
receptor recognition, viral attachment, and entry into host cells [43]. The vaccines generate
spike protein-specific antibodies, specifically anti-S IgG antibodies which have been shown
to possess neutralizing activity against the first pandemic SARS-CoV-2 Wuhan HU-1
variant [44]. Although vaccination efforts are underway, emerging variants remain a
significant cause for concern given that the antibodies generated through vaccination may
no longer recognize the mutated virus. For example, the recent VOCs B.1.1.7 (United
Kingdom) and B.1.351 (South Africa) have eight to ten amino acid changes or deletions in
the spike protein that current vaccines target [44]. Although data are still emerging, initial
studies suggest available vaccines still provide protection against current VOCs, but initial
studies have reported that antibodies produced in response to vaccination neutralize the
B.1.1.7 VOC, whereas neutralization of the B.1.351 VOC is reported to be reduced 8- to 13fold [44]. As has been shown for the B.1.351 variant, it is possible that current vaccines may
not provide the same degree of protection against current and future variants. Additionally,
current vaccines may potentially be more or less effective at reducing transmission of the
virus for different VOCs. Therefore, the reproductive processes may still remain in jeopardy,
since we do not have any evidence concerning the detection of the virus in respective sperm
samples or whether the variants will display any resistance during cryopreservation.
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5. Conclusions
Although no case exists within the human IVF community of cross-contamination
during the course of cryostorage, research has demonstrated that cross-contamination does
pose a real risk [45,46]. If we accept that the SARS-CoV-2 virus can be detected in the
semen and the virus is resistant to liquid nitrogen, as is the case with many other viruses,
maybe additional specific measures should be followed to minimize the presence of the
virus during sperm cryopreservation and any possible cross-contamination effect. Apart
from the sperm washing steps, which are commonplace, a closed cryopreservation method
could be applied to reduce the risk of cross-contamination further. This process involves
the use of a closed “sealed” system, which prevents the sperm suspension from coming
into direct contact with the liquid nitrogen and allows the cryopreservation of a relatively
larger volume of semen (and subsequently more spermatozoa) [47,48]. The closed system
for cryopreservation will all but guarantee that SARS-CoV-2 is not able to contaminate
other specimens. Moreover, variants of this virus may have different cryopreservation
characteristics, making each variant different in terms of cross-contamination ability. We
still have much to learn about the function and the effect of SARS-CoV-2 and its variants
on the various aspects of human reproduction [49]; we should be extra-cautious with the
handling of gametes and cryopreservation [50].
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